Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1915 • ACR Convergence 2021
Risk of Cardiovascular Outcomes with Low-Dose Glucocorticoids in Patients with Rheumatoid Arthritis
Brian Coburn¹, Michael George¹, Joshua Baker¹, Jesse Hsu², Qufei Wu¹, Lang Chen³, Fenglong Xie³, Huifeng Yun⁴ and Jeffrey Curtis⁵, ¹University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA, Philadelphia, PA, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Alabama Birmingham, Birmingham, AL, ⁵Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Many guidelines recommend limiting glucocorticoids to short-term use in patients with rheumatoid arthritis (RA), but up to 40% of patients remain on glucocorticoids long-term.…
Abstract Number: PP12 • ACR Convergence 2021
Fighting for the Care We Deserve: My Experience as a Latina Patient-Researcher During the COVID-19 Pandemic
Guadalupe Torres¹, Courtney Wells² and Kristine Carandang³, ¹, ²University of Wisconsin-River Falls, School of Social Work, St. Paul, MN, ³Global Healthy Living Foundation, CreakyJoints, San Diego, CA
Background/Purpose: I am a 23-year-old first generation Latina with rheumatoid arthritis (RA). Despite being disproportionately affected by rheumatic conditions, the perspectives of Latinx remain poorly…
Abstract Number: 0017 • ACR Convergence 2021
Lessons Learnt from Associations Between Anti-modified Protein Antibodies and Risk Factors: Human Leukocyte Antigen – Shared Epitope Alleles Solely Associate with Anti-citrullinated Protein Antibodies
Tineke J van wesemael, Annemarie L. Dorjee, Tom WJ Huizinga, Annette H.M van der Helm-van Mil, René Toes and Diane van der Woude, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is characterized by the presence of auto-antibodies to post translationally modified proteins (anti-modified protein antibodies (AMPA)): anti-citrullinated protein antibodies (ACPA), anti-carbamylated…
Abstract Number: 0034 • ACR Convergence 2021
Immune Complexes Contain Novel Acetylated Antigens in the Synovial Fluid of RA Patients
Khetam Ghannam¹, Holger Bang², Thomas Häupl¹, Eugen Feist³ and Gerd Burmester⁴, ¹Charite University Medicine Berlin, Berlin, Germany, ²Orgentec Diagnostika GmbH, Mainz, Germany, Mainz, Germany, ³Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ⁴Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease characterized by genetic predisposition and associated immunological features including the production of autoantibodies against various epitopes. Several…
Abstract Number: 0099 • ACR Convergence 2021
First Results of the BELCOMID Study: BELgian Cohort Study of COVID-19 in Immune Mediated Inflammatory Diseases (IMID)
Kurt de Vlam¹, Jeroen Geldhof², Marie Truyens³, Joao Sabino⁴, Marc ferrante⁴, Jo Lambert³, Hilde lapeere³, Tom hillary⁴, an Van Laethem⁴, Triana Lobaton³, severine vermeire⁴, Barbara Neerinckx¹ and Patrick Verschueren⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²University Hospital Gent, Gent, Belgium, ³university hospital gent, gent, ⁴university hospitals leuven, leuven, ⁵University Hospitals Leuven - KULeuven, Leuven, Belgium
Background/Purpose: It has been suggested that 100% of SARS-CoV2 infections leads to development of specific IgG antibodies that remain detectable for a long period of…
Abstract Number: 0173 • ACR Convergence 2021
Greater High-density Lipoprotein Levels over Time Are Linked to Lower Coronary Plaque Formation, Regression and Stabilization of High-risk Lesions in Rheumatoid Arthritis
George Karpouzas¹, sarah ormseth², Elizabeth Hernandez² and Matthew Budoff³, ¹Harbor-UCLA Medical Center, Torrance, CA, ²The Lundquist Institute, Harbor-UCLA Medical Center, Torrance, CA, ³Division of Cardiology, and the Lundquist Institute ay Harbor-UCLA Medical Center, Torrance, CA
Background/Purpose: The relationship between serum lipoproteins and cardiovascular (CV) disease risk in rheumatoid arthritis (RA) is complex. Their levels and function may vary based on…
Abstract Number: 0273 • ACR Convergence 2021
Abnormalities in Left Ventricular Geometry Influenced by Higher Rheumatoid Factor and Anti-Cyclic Citrullinated Peptide Antibody Titers in Rheumatoid Arthritis Patients
Natalia Guajardo-Jauregui, Dionicio Galarza-Delgado, Iris Colunga-Pedraza, Jose Azpiri-Lopez, Alejandra Rodriguez-Romero, Alejandro Meza-Garza, Julieta Loya-Acosta, Jesus Cardenas-de La Garza, Salvador Lugo-Perez, Catalina Andrade-Vazquez and Alan De Leon-Yañez, Hospital Universitario "Dr Jose E. Gonzalez", Monterrey, Mexico
Background/Purpose: Rheumatoid arthritis (RA) patients have a higher risk of developing left ventricular (LV) geometry abnormalities which can result in cardiac death. High titers of…
Abstract Number: 0290 • ACR Convergence 2021
Prevalence and Predictors of Mortality in Rheumatoid Arthritis-Related Lung Disease: Results from a Single Center Study
Didem Sahin Eroglu¹, Anil Colaklar², Serdar Baysal³, Murat Torgutalp¹, Asaf Baygul⁴, Serdar Sezer¹, Emine Aydemir Guloksuz¹, Mehmet Yuksel¹, Mucteba Yayla¹, Emine Uslu yurteri⁵, Caglar Uzun², Ozlem Ozdemir kumbasar⁴, Murat Turgay¹, Kinikli Gulay¹ and Askin Ates¹, ¹Ankara University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ²Ankara University Faculty of Medicine, Department of Radiology, Ankara, Turkey, ³Ankara University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ⁴Ankara University Faculty of Medicine, Department of Pulmonology, Ankara, Turkey, ⁵Hatay Training and Research Hospital, Hatay, Turkey
Background/Purpose: Rheumatoid arthritis-related lung disease (RA-LD) is a common manifestation of rheumatoid arthritis (RA) and associated with excess mortality. Many studies to date were focused…
Abstract Number: 0468 • ACR Convergence 2021
During Development of Rheumatoid Arthritis, Intermetatarsal Bursitis May Occur Before Clinical Joint Swelling: A Large MRI Study in Patients with Clinically Suspect Arthralgia
Bastiaan van Dijk¹, Fenne Wouters¹, Elise van Mulligen², Monique Reijnierse¹ and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Inflammation of the synovial lining is a hallmark of rheumatoid arthritis (RA). A synovial lining is not only present at synovial joints and tendon…
Abstract Number: 0572 • ACR Convergence 2021
Circulating Cytokines and Chemokines Are Associated with the Risk of Incident Cardiovascular Disease in Rheumatoid Arthritis Independent of Conventional Disease Activity Measures
Tate Johnson¹, Michael Duryee², Carlos Hunter², Punyasha Roul², Yangyuna Yang², Joshua Baker³, Geoffrey Thiele², Ted Mikuls² and Bryant England², ¹University of Nebraska Medical Center, Elkhorn, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Cardiovascular disease (CVD) is the leading cause of death in rheumatoid arthritis (RA). While chronic inflammation contributes to CVD pathogenesis, the role of specific…
Abstract Number: 0592 • ACR Convergence 2021
Gender Modifies the Effect of Rheumatoid Arthritis on All-Cause Mortality
Srikanta Banerjee¹ and Stephanie Falls², ¹Walden University, Leola, ²PA Department of Health, Leola
Background/Purpose: Rheumatoid arthritis (RA) is a chronic and systemic autoimmune disease which predominantly affects joints with varying severity. While RA has been found to be…
Abstract Number: 0747 • ACR Convergence 2021
Understanding Heterogeneity in Patients’ Conceptualization of Treatment for Rheumatoid Arthritis: A Cluster Analysis
Betty Hsiao¹, Julie Downs², Mandy Lanyon², Leslie Harrold³, Jeffrey Curtis⁴, Susan Blalock⁵, Carole Wiedmeyer⁶, SHILPA VENKATACHALAM⁷, William Nowell⁸ and Liana Fraenkel⁹, ¹Yale-New Haven Medical Center, New Haven, CT, ²Carnegie Mellon, Pittsburgh, PA, ³Corrona, LLC, Northborough, MA, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁵Chapel Hill, Chapel Hill, NC, ⁶Global Healthy Living Foundation, Nyack, NY, ⁷Global Healthy Living Foundation, New York, NY, ⁸Global Healthy Living Foundation, Upper Nyack, NY, ⁹Berkshire Medical Center, Lenox, MA
Background/Purpose: Uptake of treat to target strategies for the management of rheumatoid arthritis (RA) is low. While there are known system-related barriers to accessing treatment,…
Abstract Number: 0798 • ACR Convergence 2021
The Impact of Comorbidities on the Simple Disease Activity Index (SDAI) and Its Components over the First Year of Follow-up – an Analysis from the Canadian Early Arthritis Cohort (CATCH)
Lillian-Ruiheng Chen¹, Orit Schieir², Marie-France Valois³, Janet Pope⁴, Susan Bartlett³, Gilles Boire⁵, Glen Hazlewood⁶, Carol Hitchon⁷, Edward C. Keystone⁸, Diane Tin⁹, Carter Thorne¹⁰, Narcisse Singbo¹, Vivian Bykerk¹¹ and Louis Bessette¹², ¹Centre de recherche du CHU de Québec-Université Laval, Québec City, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada, ⁴University of Western Ontario, London, ON, Canada, ⁵Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁶University of Calgary, Calgary, AB, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Mount Sinai Hospital, Toronto, ON, Canada, ⁹The Arthritis Program Research Group, Newmarket, ON, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, ON, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada
Background/Purpose: Comorbid conditions have been shown to negatively influence the achievement of treatment targets in rheumatoid arthritis (RA) patients. The comorbid conditions may bias the…
Abstract Number: 0816 • ACR Convergence 2021
Analysis of Abatacept Treatment Retention and Efficacy According to Disease Duration and Treatment Line in a Real-World Setting
Rieke Alten¹, Xavier Mariette², Rene-Marc Flipo³, Roberto Caporali⁴, Maya Buch⁵, Yusuf Patel⁶, Raimon Sanmarti⁷, Sara Marsal⁸, Michael Nurmohamed⁹, Hedley Griffiths¹⁰, Peter Peichl¹¹, Bettina Bannert¹², Adrian Forster¹³, Melanie Chartier¹⁴, Yedid Elbez¹⁵, Christiane Rauch¹⁶, Vadim Khaychuk¹⁷ and Karissa Lozenski¹⁷, ¹Schlosspark-Klinik University, Berlin, Germany, ²Université Paris-Saclay, AP-HP, Hospital Bicêtre, Paris, France, ³Centre Hospitalier Universitaire de France, Lille, France, ⁴Policlinico S. Matteo University, Pavia, Italy, ⁵University of Leeds, Leeds, United Kingdom, ⁶Hull Royal Infirmary, Hull, United Kingdom, ⁷Hospital Clínic de Barcelona, Barcelona, Spain, ⁸Hospital Universitari Vall d’Hebron, Barcelona, Spain, ⁹ARC Amsterdam University Hospitals – VU University Medical & Reade, Amsterdam, Netherlands, ¹⁰Barwon Rheumatology Service, Geelong, Australia, ¹¹Evangelical Hospital, Vienna, Austria, ¹²Universitätsspital Basel, Basel, Switzerland, ¹³Schulthess Klinik, Zürich, Switzerland, ¹⁴Bristol Myers Squibb, Rueil-Malmaison, France, ¹⁵Deepscover, Puteaux, France, ¹⁶Bristol Myers Squibb, Munich, Germany, ¹⁷Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Longer disease duration and greater number of prior DMARDs have been associated with lower treatment efficacy in patients with RA.1 Abatacept is a biologic…
Abstract Number: 0833 • ACR Convergence 2021
Effectiveness of Upadacitinib in Patients with Rheumatoid Arthritis in German Real-World Practice: Interim Results from a Post-Marketing Observational Study
Torsten Witte¹, Uta Kiltz², Florian Haas³, Elke Riechers⁴, Ulrich Prothmann⁵, Daniela Adolf⁶, Carsten Holland⁷, Rouven Hecht⁸, Alexander Rössler⁷, Kirsten Famulla⁸, Konrad Götz⁸ and Klaus Krüger⁹, ¹Hannover Medical School, Hannover, Germany, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³Internistisch-Rheumatologische Facharztpraxis, Tübingen, Germany, ⁴Department for Rheumatology and Immunology, Hannover Medical University, Hannover, ⁵Knappschaftsklinikum Saar, Püttlingen, Germany, ⁶StatConsult GmbH, Biometry and Data Management, Magdeburg, Germany, ⁷AbbVie Deutschland GmbH & Co. KG, Wiesbaden, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹Rheumatological Practice Center, Munich, Germany
Background/Purpose: Upadacitinib (UPA) is a Janus kinase inhibitor that has been shown to be effective and well tolerated in patients with rheumatoid arthritis (RA) in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].